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Supplemental Figures 
 
 Fig S1. Compound 011A is shown as a stick figure while the antibiotics used in this study 
are shown in 3D ball and stick figures. 
  
Fig S2. Alignment of E. coli MscL and 7 pathogens. The multisequence analysis was 
performed using Clustal Omega, Multiple Sequence Alignment tool from The European 
Bioinformatics Institute (EMBL-EBI) and edited with Jalview. The region that compound 011A 
binds is indicated by the two red bars above the sequences; note these are among the most 
conserved. 
  
  
Fig. S3. Shown are M. smegmatis MC2155, MC2155 ΔmscL and MC1255 ΔmscL + pNH02 
(expressing MscL) strains; cells were induced for 8 hours with 0.2% acetamide. Cells carrying the 
plasmid they were constantly grown in the presence of 100ug/ml of HygR (liquid and plates). The 
protocol was as in the experimental erocedures with the exception that 80 µM of 011A was used 
and the incubation with compound was 5 hrs. The percentage viability % reduction of colony 
forming units for each condition is plotted. ****p < 10-6 
 
  
  
 
Fig S4. Compound 011A can be used as an adjuvant to increase the potency of DHS. 
Minimal inhibitory concentration curves are shown in log scale in the MJF455 cell line for 
compound 011A, in the presence or the absence of 0.5 µM DHS. Bacterial cultures carrying empty 
plasmid or expressing Eco-MscL are shown as indicated. Values are expressed as the 
percentage of decreased growth (OD600) in the presence of compound 011A, relative to non-
treated.  
 
 
 Fig S5. The “start line” of DHS the passing through MscL competition and the trajectories 
of distances and the radius of five K106 residues in a representative MD run  
A. DHS shown at top (periplasm) in green sticks is initially placed in the center of the periplasmic 
loops, while the 011A compound, shown in orange/brown sticks, is positioned at the best docking 
pose. The coordinate centers of DHS and five lysine residues (residue IDs: 106, 242, 378, 514 
and 650, shown in blue sticks) are shown in magenta spheres. The distances between the two 
centers are calculated to monitor the passage of DHS through the MscL channel.  
B.  The dynamics of the distance between the two centers along the MD simulation time scale. It 
is demonstrated that the first passage of DHS through MscL occur around 6000 picoseconds. 
C.  The dynamics of the radius of the cycle formed by the -carbons of the five lysine residues 
plotted along the MD simulation time. It is illustrated that the cycle becomes smaller when the 
MscL pore is partially opened.  
 
 
  
  
Fig S6. In an MD simulation, average distances between the coordinate centers of 
Streptomycin and the five Lys residues (106, 242, 378, 514 and 650) along the simulation 
time are plotted. With 011A bound to MscL (red curve), more movement is observed than 
simulations without 011A (black). 
  
  
Fig S7.  011A can stabilize the partially open structure  
A. A representative partially open conformation collected during the “passing through” 
experiments. Streptomycin and 011A are colored using green and brown sticks, respectively; 
surrounding residues of 011A are shown as blue sticks.   
B. RMSD ~ Simulation Time plot for MD simulation without streptomycin or 011A. 
C. RMSD ~ Simulation Time plot for MD simulation with 011A bound to MscL without 
streptomycin. The reference structure in RMSD calculations is the partially open structure shown 
in Panel A. When 011A is bound to MscL, the main chain RMSDs of the MscL secondary 
structures are smaller than 2.5 Å for MD simulation times up to 70 nanoseconds (red curve of 
Panel C); in contrast, the main chain RMSDs are larger than 2.5 Å only after 10 
nanoseconds (red curve of Panel B).   
 Fig S8. Compound 011A used as an adjuvant decreases the viability of Hin-MscL 
expressing E. coli cells.  Viability experiments done with samples treated with 80 µM 
compound 011A, 2.25 µM DHS or a combination of the two in the curve of Fig 6 A. Values 
represent the percentage of colony forming units (CFU) in the presence of compound 011A, 
DHS or both, relative to the non-treated samples. Bacterial cultures carrying empty plasmid 
control (grey) or expressing Hin-MscL (green) are shown.  Note that Hin-MscL construct with the 
combination of both 011A and DHS have a significant reduction in viability when compared to 
either of the single treatments. n = 3, ** p<.005, ***p< .0005, ****p <.00005 as indicated, 2-
tailed, paired T test. 
Methods: The E. coli MJF455 strain, grown in CphM, carrying either pb10d empty vector or 
expressing WT Hin-MscL were used. Samples were obtained from the concentration curves 
described above after the final 16 to 17-hour incubation and OD620 were obtained. After which the 
cultures were diluted 1:20, followed by six consecutive 1:10 serial dilutions in the same pre-
warmed media. These diluted cultures were then plated on LB+ Amp plates and grown overnight 
in a 37°C incubator. Colony-forming units were then counted and averaged per experiment. 
 
 Fig S9. Compound 011A has no effect on the viability of HEK 293 cells. (A) Images of HEK 
293 cells in the absence (NT) or presence of DMSO only (DMSO), and (20 µM-100 µM) varying 
concentrations of compound 011A diluted in a final concentration of 1% DMSO for 48 hours. (B) 
Results from trypan blue exclusion tests after 48-hour treatment for each condition in A are shown 
as a percentage of viable cells. No significant difference was seen compared to non-treated cells 
(NT). Note that images were taken and membrane viability was tested by trypan blue exclusion 
after both 24 and 48 hours; although the 48-hour time point is shown, similar visually healthy cells 
and indistinguishable viability was observed at both time points. 
Methods: HEK 293 cells (ATCC) were plated in 24-well plates, and grown in DMEM (Sigma 
Aldrich St. Louis, MO), with the addition of 10% FBS (Sigma Aldrich St. Louis, MO) and Penicillin-
Streptomycin at a final concentration of 100 units penicillin, 0.1mg streptomycin/ml (Sigma Aldrich 
St. Louis, MO), and placed in a 37 °C incubator containing 5% CO2.  After 2 days of growth 
compound 011A was added at varying concentrations with a final DMSO concentration of 1% 
except for the non-treated wells. In brief, media was removed and centrifuged to collect any cells 
present; this is then combined with the adherent cells, which are harvested and re-suspended in 
serum free media. Equal volumes of 0.4% Trypan Blue (Sigma Aldrich St. Louis, MO) and cells 
suspension were mixed. 10ul of the mixture was then placed on a hemacytometer. Both total cells 
and stained cells were counted under a microscope and membrane permeabilization/viability 
determined.  
Table S1: Primers used in this study.  
Primer Sequence Purpose 
pGK_F tcggtcggcccgtagagaATGAGTCTGAAAGAAAAAA Amplification of GalK 
pGK_R AGCAGGACAGTGCTGAttggcgatcccg "" 
pNH01GK_
F ttggcgatcccgaccgcagcacc 
Amplification of pNH01 for GalK 
insertion 
pNH01GK_
R gtcgcctcggtcggcccgtagaga "" 
pMscLU_F atttgctagccatggGgctgatcgccagcga Amplification of MscL upstream 
pMscLU_R atttgctagccatggGgctgatcgccagcga "" 
pMscLD_F aggacgaagcggatcctggcggagaacagca Amplification of MscL downstream 
pMscLD_R cggccacgatgtacttcgcctcaacaaggggct "" 
pCPCR_F ctgccttcaccggcctggtc Unmarking verification 
pCPCR_R ggttccacagggaagc "" 
MsMscL_F tccagggcgccatggcgatgttgaagggcttc Amplification of MscL gene  
MsMscL_R tccggtaccttatcgtttaggaggtgcggtcgc “” 
 
